Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

ExpreS2ion Biotech cuts Q2 loss, early HER2 data show immune response without safety concerns

ExpreS2ion Biotech reported a net loss of SEK 9.7m in the second quarter versus SEK 10m a year earlier, while the operating loss rose slightly to SEK 12m. Operating income increased to SEK 11.5m, driven by grants, and R&D expenses climbed to SEK 11.4m (+483%) as the HER2 program ES2B‑C001 was advanced. In the Phase I trial, 12 of 13 evaluable patients showed drug‑specific antibody responses with no new safety signals; a Phase II start is now expected in H2 2027. The company completed a rights issue and had SEK 34.4m in cash at quarter‑end, but remains operationally loss‑making and reliant on grant funding and partner interest. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2015, EXPRES2ION BIOTECH HLDG has already paid €98.95 in dividends. The last payout was in April 2015.

Financials

In the last quarter, EXPRES2ION BIOTECH HLDG had revenue of €181.47k and net profit of -€875.39k

(EUR)	June 2026	YoY
Revenue	181.47k	31.55%
Gross profit	-916.18k	3,996.37%
Net profit	-875.39k	2.70%
EBITDA	-1.92m	89.44%

Fundamentals

Metric	Value
Market capitalization	€240.71k
Number of shares	2.55m
52-week high/low	€2.04 - €0.0878
Dividends	No
Beta	2.21
P/E ratio	-0.15
PEG ratio	0.00
P/B ratio	0.91
P/S ratio	0.70

Company profile

ExpreS2ion Biotech Holding AB (publ) entwickelt und produziert über ihre Tochtergesellschaft ExpreS2 ion Biotechnologies ApS in Dänemark komplexe Proteine für Impfstoffe und Diagnostika. Das Unternehmen entwickelt den Impfstoff COVID-19, der sich in Phase II der klinischen Prüfung befindet. Außerdem entwickelt es einen Grippe- und Brustkrebsimpfstoff, der sich in der klinischen Phase II befindet, sowie einen Malariaimpfstoff. Darüber hinaus lizenziert das Unternehmen seine ExpreS2-Plattform an Forschungsinstitute und Pharmaunternehmen. Die ExpreS2ion Biotech Holding AB (publ) wurde 2015 gegründet und hat ihren Sitz in Horsholm, Dänemark.